Collectively, these results indicate that YHO-1701 effectively suppresses cell adaptation to ALK-TKIs driven by STAT3 re-activation and induces apoptosis in residual ALK-rearranged lung cancer cells (Fig. 3h). Here, ALK is linked to lung carcinoma.